Sangamo Therapeutics, Inc. (SGMO) Financial Analysis & Valuation | Quarter Chart
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP)... more
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science i... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $30.66M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Alexander D. Macrae Ch.B |
| IPO Date | 2000-04-06 | CAGR | 15.33% |
| Employees | 127 | Website | www.sangamo.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SGMO chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $34.08M | P/E | -0.2 | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/CF | — | P/FCF | — |
| Sales | $34.56M | Sales 1Y | -45.8% | Sales 3Y | -85.66% | Sales 5Y | -73.7% |
| EPS | $-0.37 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | -89.87% | EPS QoQ | -27.27% | Sales QoQ Avg | 586.64% | EPS QoQ Avg | -7.58% |
| Gross Margin | 100% | Operating Margin | -319.25% | Profit Margin | -356.89% | ROCE | -1615.02% |
| ROA | -206% | ROE | 6686% | Altman Z Score | -44.45 | Piotroski Score | 1 |
| Current Ratio | 0.7 | Quick Ratio | 0.7 | Cash Ratio | 0.52 | Op. CF Ratio | -0.36 |
| Debt/Equity | -1.02 | Debt/Assets | 0.32 | Lt Debt/Equity | -1.02 | Lt Debt/Cap. | 51.28 |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.58 | Receivables Turnover | 39.58 |
| Enterprise Value | $34.08M | P/E Ratio | -0.2 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-0.37 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -45.8% | Gross Margin | 100% |
| Operating Margin | -319.25% | Profit Margin | -356.89% |
| ROE | 6686% | ROA | -206% |
| ROCE | -1615.02% | Current Ratio | 0.7 |
| Quick Ratio | 0.7 | Cash Ratio | 0.52 |
| Debt/Equity | -1.02 | Interest Coverage | — |
| Altman Z Score | -44.45 | Piotroski Score | 1 |
Sangamo Therapeutics, Inc. (SGMO) valuation & financials
Sangamo Therapeutics, Inc. (SGMO) has a market capitalization of $30.66M and trades at a price-to-earnings ratio of -0.2. It operates in the Healthcare sector (Biotechnology).
Sangamo Therapeutics, Inc.'s revenue grew -45.8% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)